Hostname: page-component-745bb68f8f-5r2nc Total loading time: 0 Render date: 2025-01-27T04:25:31.807Z Has data issue: false hasContentIssue false
  • English
  • Français

A Double-blind Comparative Trial of Moclobemide v. Imipramine and Placebo in Major Depressive Episodes

Published online by Cambridge University Press:  06 August 2018

M. Versiani ,
U. Oggero ,
P. Alterwain ,
R. Capponi ,
F. Dajas ,
G. Heinze-Martin ,
C.A. Marquez ,
M.A. Poleo ,
L.E. Rivero-Almanzor  and
L. Rossel
...Show all authors
M. Versiani
Affiliation:
Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro, Brazil
U. Oggero
Affiliation:
Juiz de Forta — MG, Brazil
P. Alterwain
Affiliation:
Br. Artigas, Montevideo, Uruguay
R. Capponi
Affiliation:
Hospital Sanatorio El Peral Psiquiatria, Santiago de Chile, Chile
F. Dajas
Affiliation:
Neurochemistry Division, Instituto de investigaciones biologicas clemente estable, Montevideo, Uruguay
G. Heinze-Martin
Affiliation:
Hospital General Adolfo Lopez Mateos, Mexico
C.A. Marquez
Affiliation:
Instituto Privado de Psicopatologia, Buenos Aires, Argentina
M.A. Poleo
Affiliation:
Los Palos Grandes, Caracas, Venezuela
L.E. Rivero-Almanzor
Affiliation:
Hospital Psiquiatrico San Juan de Dios, Mexico City, Mexico
L. Rossel
Affiliation:
Centro Cientifico de Desarrollo Psicologico, Santiago de Chile, Chile
W. Schmid-Burgk
Affiliation:
F. Hoffmann-La Roche Ltd, Basel, Switzerland
R. Ucha-Udabe
Affiliation:
Instituto Privado de Psicopatologia, Buenos Aires, Argentina
Get access Rights & Permissions [Opens in a new window]

Abstract

Patients (n = 490) suffering from a major depressive episode according to DSM-III criteria were randomly allocated to groups receiving either moclobemide, imipramine, or placebo treatment. Subjects were treated as out-patients for 6 weeks. On overall assessment of efficacy and on results of the Hamilton Rating Scale for Depression, both moclobemide and imipramine were superior to placebo, but the differences between moclobemide and imipramine were not significant. Premature termination due to insufficient efficacy was more frequent with placebo than with moclobemide or with imipramine, these differences being significant. The overall assessment of tolerance clearly favoured placebo and moclobemide over imipramine. This was also reflected in the frequency of premature terminations due to poor tolerance, as well as in the frequency of adverse events, which were highest in the imipramine group. The only cardiovascular finding was an increase of the mean heart rate with imipramine, maximum at the end of week 1, while placebo and moclobemide displayed no relevant changes. There were no other important drug-related changes.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 155 , Issue S6: Depression and Reversible Monoamine Oxidase Inhibitors-New Perspectives , October 1989 , pp. 72 - 77
Copyright
Copyright © 1989 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

British Medical Research Council (1965) Clinical trial of the treatment of depressive illness. British Medical Journal, 1, 881–886.Google Scholar
Burkard, W.P., Bonetti, E.P., Da Prada, M., et al (1989) Pharmacological profile of moclobemide. a short-acting and reversible inhibitor of monoamine oxidase type A. Journal of Pharmacology and Experimental Therapeutics, 248(1), 391–399.Google Scholar
Casacchia, M., Carolei, A., Barba, C., et al (1984) A placebo-controlled study of the antidepressant activity of moclobemide. a new MAO-A inhibitor. Pharmacopsychiatry, 17, 122–125.CrossRefGoogle ScholarPubMed
Gieschke, R., Schmid-Burgk, W. & Amrein, R. (1988) Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine. Journal of Neural Transmission, 26, (Suppl.), 97–104.Google Scholar
Keller, H.H., Kettler, R., Keller, G., et al (1987) Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16–6491. Naunyn-Schmiedeberg's Archives of Pharmacology, 335, 12–20.CrossRefGoogle ScholarPubMed
Kilch, L.G., Andrews, G. & Neilson, M. (1988) The long term outcome of depressive illness. British Journal of Psychiatry, 153, 752–757.Google Scholar
Larsen, J.K., Holm, P. & Mikkelsen, P.L. (1984) Moclobemide and clomipramine in the treatment of depression. Acta Psychiatrica Scandinavica, 70, 254–260.Google Scholar
Lee, A.S. & Murray, R.M. (1988) The long-term outcome of Maudsley depressives. British Journal of Psychiatry, 153, 741–751.Google Scholar
Norman, T.R., Ames, D., Burrows, G.D., et al (1985) A controlled study of a specific MAO-A reversible inhibitor (Ro 11–1163) and amitriptyline in depressive illness. Journal of Affective Disorders, 8, 29–35.CrossRefGoogle ScholarPubMed
Schmid-Burgk, W., Gieschke, R., Allen, S., et al (1988) Moclobemide, a new reversible MAO-inhibitor and the problem of tyramine interaction studies. Current Therapeutic Research, 43(5), 903–917.Google Scholar
Stefanis, C.N., Alevizos, B. & Papadimitriou, G. (1984) Moclobemide (Ro 11–1163) versus desipramine: a double-blind study in depressive patients. In: Monoamine Oxidase and Disease, Prospects for Therapy with Reversible Inhibitors. London: Academic Press.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.